Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611630 | 1.00 | LMNA (0.50) | LMNAKMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL10712606 | 0.83 | ALDH1A1 (0.63) | LMNAKMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL34472041 | 0.82 | L3MBTL1 (0.47) | LMNAKMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL29838495 | 0.82 | L3MBTL1 (0.50) | KMT2AALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL5464387 | 0.82 | L3MBTL1 (0.50) | KMT2AALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL30521352 | 0.80 | L3MBTL1 (0.53) | LMNAKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28130105 | 0.80 | LMNA (0.55) | LMNAKMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL17856110 | 0.80 | L3MBTL1 (0.53) | LMNAKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15215634 | 0.79 | ALDH1A1 (0.47) | LMNAKMT2AEPHX2ALDH1A1KDM4E | |
| SCHEMBL20560664 | 0.79 | EPHX2 (0.51) | LMNAKMT2AEPHX2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867251-B1 | KRAS G12C INHIBITORS | LILLY CO ELI (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-112805281-B | KRAS G12C inhibitors | 伊莱利利公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-112805281-A | KRAS G12C inhibitors | 伊莱利利公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020081282-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081282-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20200115375-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2020-04-16 | — | — | US | disclosed |
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2019-08-20 | — | — | US | disclosed |
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-10-04 | — | — | US | disclosed |
| CN-107466296-A | Imidazo [2,1 b] thiazole and 5,6 glyoxalidine as S100 inhibitor simultaneously [2,1 b] thiazole | 活跃生物技术有限公司 | 2017-12-12 | — | — | CN | disclosed |
| WO-2016042172-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-03-24 | — | — | WO | disclosed |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1467981-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | Kylix Pharmaceuticals B.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062215-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | KYLIX PHARMACEUTICALS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| US-4713382-A | N-phenyl-4-phenyl-1-piperazinecarboxamidines and related compounds as antiarrhythmic agents | SYNTEX (U.S.A.) INC. (US) | 1987-12-15 | — | — | US | disclosed |
| EP-0204265-A1 | N-Phenyl-4-phenyl-1-piperazine carboxamidines and related compounds as antiarrhythmic agents | LABORATOIRES SYNTEX S.A. (FR) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282348-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | S100B, S100P, S100A4 | LMNA 4388/4885KMT2A 2868/4885EPHX2 3370/4885 |
| US-20200115375-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 3026/4885KMT2A 1574/4885EPHX2 2857/4885 |
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | S100B, S100P, S100A4 | LMNA 4388/4885KMT2A 2868/4885EPHX2 3370/4885 |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | LMNA 2932/4885KMT2A 792/4885EPHX2 3017/4885 |
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LMNA 3026/4885KMT2A 1574/4885EPHX2 2857/4885 |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | LMNA 493/4885KMT2A 3041/4885EPHX2 386/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | LMNA 289/4885KMT2A 2961/4885EPHX2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.